Jose Javier Sanchez
Overview
Explore the profile of Jose Javier Sanchez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
5520
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Casado E, Moreno Garcia V, Sanchez J, Gomez Del Pulgar M, Feliu J, Maurel J, et al.
Int J Radiat Oncol Biol Phys
. 2012 Apr;
84(5):1151-8.
PMID: 22516806
Purpose: Management of locally advanced rectal cancer (RC) consists of neoadjuvant chemoradiotherapy (CRT) with fluoropyrimidines, followed by total mesorectal excision. We sought to evaluate the expression of selected genes, some...
12.
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al.
Lancet Oncol
. 2012 Jan;
13(3):239-46.
PMID: 22285168
Background: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations. We...
13.
Balana C, Carrato C, Ramirez J, Cardona A, Berdiel M, Sanchez J, et al.
Clin Transl Oncol
. 2011 Aug;
13(9):677-85.
PMID: 21865140
Introduction: Methylation of the promoter of the MGMT gene and MGMT protein expression are recognized as predictive markers for response to alkylating chemotherapy in glioblastoma (GB). Material And Methods: We...
14.
Wei J, Costa C, Ding Y, Zou Z, Yu L, Sanchez J, et al.
J Natl Cancer Inst
. 2011 Aug;
103(20):1552-6.
PMID: 21862729
Breast cancer susceptibility gene 1 (BRCA1) has a central role in chemotherapy-induced DNA damage response. The protein inhibitor of activated STAT (PIAS) family of proteins, PIAS1 and PIAS4, are also...
15.
Jantus-Lewintre E, Sanmartin E, Sirera R, Blasco A, Sanchez J, Taron M, et al.
Lung Cancer
. 2011 Apr;
74(2):326-31.
PMID: 21481963
Introduction: The vascular endothelial growth factor (VEGF) family of ligands and receptors (VEGFR) play an important role in tumor angiogenesis. Increased expression of angiogenic factors in tumors or in blood...
16.
Casado E, Moreno Garcia V, Sanchez J, Blanco M, Maurel J, Feliu J, et al.
Clin Cancer Res
. 2011 Apr;
17(12):4145-54.
PMID: 21467161
Purpose: Preoperative chemoradiotherapy (CRT) is the treatment of choice for rectal cancer (RC), but half of the patients do not respond, suffer unnecessary toxicities, and surgery delays. We aimed to...
17.
Sirera R, Bremnes R, Cabrera A, Jantus-Lewintre E, Sanmartin E, Blasco A, et al.
J Thorac Oncol
. 2011 Jan;
6(2):286-90.
PMID: 21252717
Background: Circulating DNA is observed at higher concentrations in patients with lung cancer than in controls. Qualitative and quantitative analysis of circulating DNA is a promising noninvasive tool. Our aim...
18.
Rosell R, Molina M, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, et al.
Clin Cancer Res
. 2011 Jan;
17(5):1160-8.
PMID: 21233402
Purpose: Advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations (deletion in exon 19 or L858R) show an impressive progression-free survival of 14 months when treated...
19.
Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer
Simonetti S, Molina M, Queralt C, de Aguirre I, Mayo C, Bertran-Alamillo J, et al.
J Transl Med
. 2010 Dec;
8:135.
PMID: 21167064
Background: Immunohistochemistry (IHC) with mutation-specific antibodies may be an ancillary method of detecting EGFR mutations in lung cancer patients. Methods: EGFR mutation status was analyzed by DNA assays, and compared...
20.
Salazar F, Molina M, Sanchez-Ronco M, Moran T, Ramirez J, Miguel Sanchez J, et al.
Lung Cancer
. 2010 Aug;
72(1):84-91.
PMID: 20705357
The potential differential effect of first-line treatment and molecular mechanisms on survival to second-line chemotherapy or EGFR tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC) has not been fully...